<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03353922</url>
  </required_header>
  <id_info>
    <org_study_id>NR115</org_study_id>
    <nct_id>NCT03353922</nct_id>
  </id_info>
  <brief_title>Driving Simulation to Assess Non-Sedative Effects of Tolperisone</brief_title>
  <official_title>Driving Simulation Cross-Over Study of Sedative Effects of Tolperisone Compared to Cyclobenzaprine and Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurana Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cognitive Research Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Neurana Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized blinded study to assess the sedative effect of 150 mg TID tolperisone&#xD;
      and 10 mg TID cyclobenzaprine compared to placebo on simulated driving performance and&#xD;
      cognitive functioning in healthy adult volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, placebo-controlled, multiple-dose 3-way cross-over study of the&#xD;
      safety and cognitive effects of multiple doses of 150 mg tolperisone administered TID in 30&#xD;
      male and female healthy volunteers. Treatment groups include 450 mg tolperisone (i.e., 150 mg&#xD;
      administered three times daily), 30 mg cyclobenzaprine (i.e., 10 mg administered three times&#xD;
      daily), and placebo. Subjects will receive 3 days of each treatment.&#xD;
&#xD;
      Subject participation will be approximately 3 weeks as outpatients with 3 days each week as&#xD;
      overnight clinic participants.&#xD;
&#xD;
      In this crossover study, treatment effects will be assessed following the second initial&#xD;
      dose, the morning following nighttime dosing (to assess residual next day effects), and at&#xD;
      steady state (i.e., following AM dosing on Day 3).&#xD;
&#xD;
      Subjects will be dosed on the morning of Day 1. Approximately one hour after the second dose&#xD;
      on Day 1, subjects will be administered the cognitive test, followed by the driving simulator&#xD;
      examination.&#xD;
&#xD;
      On the morning of Day 2, prior to dosing, subjects will be readministered the cognitive test&#xD;
      and driving examination to assess residual next day effects.&#xD;
&#xD;
      Subjects will repeat cognitive testing and the driving examination on the morning of Day 3,&#xD;
      after administration of the AM study medication, to evaluate the cumulative effects of 3 days&#xD;
      of dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2017</start_date>
  <completion_date type="Actual">January 30, 2018</completion_date>
  <primary_completion_date type="Actual">December 6, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>multiple-dose 3-way cross-over study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>subjects are blindfolded to receive oral dose of treatment, matching placebo, or unblinded active control</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Standard Deviation of Lateral Position (SDLP)</measure>
    <time_frame>at time of peak concentration of drug (Tmax) on Day 1</time_frame>
    <description>In this crossover study, treatment effects were assessed following initial dose, the morning following nighttime dosing (to assess residual next day effects), and at steady state (i.e., following AM dosing on Day 3).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Standard Deviation of Lateral Position (SDLP) in Simulated Driving Test of Tolperisone Compared to Placebo on Day 2 Next Day Residual Effect</measure>
    <time_frame>in the morning predose on Day 2 following nighttime dosing</time_frame>
    <description>SDLP measured by simulated driving performance of tolperisone compared to placebo on Day 2 prior to morning dosing to determine the next day residual effect or hangover of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleepiness Endpoint Karolinska Sleepiness Scale KSS</measure>
    <time_frame>at Tmax on Day 1</time_frame>
    <description>assessment of self-reported motivation for driving performance where 1 equals alert and 9 equals extremely sleepy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady State Standard Deviation of Lateral Position (SDLP) Day 3</measure>
    <time_frame>Day 3</time_frame>
    <description>SDLP measured on Day 3 at steady state following 3 days of dosing three times per day to achieve steady state drug concentration and effect on outcomes</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Driving Impaired</condition>
  <arm_group>
    <arm_group_label>Tolperisone HCl 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg tolperisone tablets or cyclobenzaprine 10 mg oral tablet administered by mouth every 8 hours for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sugar pills administered by mouth every 8 hours for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclobenzaprine 10 mg oral tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg cyclobenzapine tablets administered by mouth every 8 hours for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclobenzaprine 10 Mg Oral Tablet</intervention_name>
    <description>cyclobenzaprine 10 mg tablets</description>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
    <arm_group_label>Tolperisone HCl 150 mg</arm_group_label>
    <other_name>Flexeril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>sugar pill</description>
    <arm_group_label>Cyclobenzaprine 10 mg oral tablet</arm_group_label>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
    <arm_group_label>Tolperisone HCl 150 mg</arm_group_label>
    <other_name>tolperisone matching placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All healthy volunteer subjects must be in general good health based on screening&#xD;
             physical examination (defined as the absence of any clinically relevant&#xD;
             abnormalities), medical history, 12-lead ECG, and clinical laboratory values&#xD;
             (hematology, serum chemistry and urinalysis).&#xD;
&#xD;
          2. All subjects must be capable of understanding and complying with the protocol and have&#xD;
             signed the informed consent document. Female subjects of childbearing potential must&#xD;
             sign the Women of Childbearing Potential Addendum to the informed consent form.&#xD;
&#xD;
          3. Subjects are required to have a body mass index (BMI) of 18 to 32 kg/m2, inclusive, at&#xD;
             Screening.&#xD;
&#xD;
          4. Subject must be able to reliably perform study assessments (i.e., SDLP no higher than&#xD;
             1 standard deviation greater than the mean for normal healthy adults completing the&#xD;
             CVDA practice scenario; and number correct on CogScreen Symbol Digit Coding no less&#xD;
             than 1 standard deviation below the mean for healthy adults in the 21-55 year age&#xD;
             range); demonstrates the ability to understand task instructions (in English), and be&#xD;
             physically capable (e.g., adequate manual dexterity, vision, and hearing), cognitively&#xD;
             capable and motivated to perform study tasks.&#xD;
&#xD;
          5. Subject must possess a valid driver's license and be an active driver, and have driven&#xD;
             a minimum of 10,000 miles (about 16,000 km) per year for the previous 3 years.&#xD;
&#xD;
          6. Subject must also demonstrate simulator sickness questionnaire scores which are not&#xD;
             indicative of simulator sickness as defined in the driving simulation operations&#xD;
             manual.&#xD;
&#xD;
          7. Subject must have a regular sleep pattern, not be engaged in shift-work, and in&#xD;
             general, have at least 7 hours of sleep each night (bedtime occurs between 21:00 and&#xD;
             24:00 hours).&#xD;
&#xD;
          8. Subject has a score &lt; 10 on the Epworth Sleepiness Scale (ESS).&#xD;
&#xD;
          9. Subjects must be willing and able to comply with scheduled visits, treatment plan,&#xD;
             laboratory tests, and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have any clinically significant unstable medical abnormality, chronic&#xD;
             disease or a history of a clinically significant abnormality of the cardiovascular,&#xD;
             gastrointestinal, respiratory, hepatic, or renal systems.&#xD;
&#xD;
          2. Subjects who test positive at screening for hepatitis B surface antigen, hepatitis C&#xD;
             antibody or have a history of a positive result.&#xD;
&#xD;
          3. Subjects who are known to be seropositive or test positive at Screening for Human&#xD;
             immunodeficiency virus (HIV).&#xD;
&#xD;
          4. Female subjects who are pregnant or lactating.&#xD;
&#xD;
          5. Subjects who have a disorder or history of a condition (e.g., malabsorption,&#xD;
             gastrointestinal surgery) that may interfere with drug absorption, distribution,&#xD;
             metabolism, or excretion.&#xD;
&#xD;
          6. A history within 2 years of, or current treatment for a sleeping disorder (including&#xD;
             excessive snoring, obstructive sleep apnea), or a chronic painful condition that&#xD;
             interferes with the subject's sleep.&#xD;
&#xD;
          7. A history of difficulty in falling asleep or staying asleep in the previous 3 months,&#xD;
             that is considered clinically significant by the investigator.&#xD;
&#xD;
          8. Subjects who have a history or diagnosis of any of the following conditions:&#xD;
&#xD;
               1. Primary or secondary insomnia&#xD;
&#xD;
               2. Narcolepsy&#xD;
&#xD;
               3. Cataplexy (familial or idiopathic)&#xD;
&#xD;
               4. Circadian Rhythm Sleep Disorder&#xD;
&#xD;
               5. Parasomnia including nightmare disorder, sleep terror disorder, sleepwalking&#xD;
                  disorder, and rapid eye movement behavior disorder&#xD;
&#xD;
               6. Sleep-related Breathing Disorder (obstructive or central sleep apnea syndrome,&#xD;
                  central alveolar hypoventilation syndrome)&#xD;
&#xD;
               7. Periodic Limb Movement Disorder&#xD;
&#xD;
               8. Restless Legs Syndrome&#xD;
&#xD;
               9. Primary Hypersomnia&#xD;
&#xD;
              10. Excessive Daytime Sleepiness (EDS)&#xD;
&#xD;
              11. Subject has visual or auditory impairment which in the opinion of the&#xD;
                  investigator would interfere with study related procedures or study conduct.&#xD;
&#xD;
          9. Subjects expected to use any other medication or dietary supplement to promote sleep&#xD;
             including over-the-counter sleep medications, during their participation in the study.&#xD;
&#xD;
         10. Subjects who have participated in any investigational study within 30 days prior to&#xD;
             screening or are currently participating in another clinical trial.&#xD;
&#xD;
         11. Subjects who have had a recent history (less than 2 years before entering the study)&#xD;
             of drug or alcohol abuse, or current positive urine drug screen. Alcohol abuse is&#xD;
             defined as current consumption of more than three alcoholic beverages per day.&#xD;
&#xD;
         12. Subjects who have a history of allergic reaction to tolperisone or cyclobenzaprine or&#xD;
             any components of these study medications.&#xD;
&#xD;
         13. Use of psychoactive prescription or non-prescription medications, psychoactive&#xD;
             nutritional supplements or herbal preparations within 2 weeks or 5 half-lives&#xD;
             (whichever is longer) of admission to the Clinical Research Unit (CRU) on Day 1.&#xD;
&#xD;
         14. Presence of a medical or psychiatric condition which could jeopardize the safety of&#xD;
             the subject or validity of study results&#xD;
&#xD;
         15. Subjects who consume excessive amounts of coffee, tea, cola, or other caffeinated&#xD;
             beverages per day. Excessive amount is defined as greater than 6 servings per day&#xD;
             (where 1 serving is approximately equivalent to 120 mg of caffeine).&#xD;
&#xD;
         16. Subjects who will be working a night shift within 1 week of a visit.&#xD;
&#xD;
         17. Subject who have traveled across 1 or more time zones (transmeridian travel) in the&#xD;
             last 2 weeks prior to randomization or is expected to travel across 1 or more time&#xD;
             zones during the study.&#xD;
&#xD;
         18. Current smoker (&gt;10 cigarettes or eCigarettes, 3 cigars, or 3 pipes per day) and&#xD;
             unwilling to refrain from smoking while confined to the CRU for periods of 3 days.&#xD;
&#xD;
         19. Subjects who have an inability or unwillingness to abide by the study protocol or&#xD;
             cooperate fully with the Investigator or designee.&#xD;
&#xD;
         20. Subjects who are a staff member or relative of a staff member.&#xD;
&#xD;
         21. Inability or unwillingness to use adequate contraception (as defined in item 10 of the&#xD;
             Inclusion Criteria) during and for 1 month following completion of the study.&#xD;
&#xD;
         22. Has a positive screen for alcohol or other drugs of abuse (amphetamines,&#xD;
             methamphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, opiates).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Russell Rosenberg, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NeuroTrials Research, Atlanta GA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Walling, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Collaborative Neuroscience Network, Garden Grove, CA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroTrials Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2017</study_first_posted>
  <results_first_submitted>October 11, 2018</results_first_submitted>
  <results_first_submitted_qc>September 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 20, 2020</results_first_posted>
  <last_update_submitted>September 25, 2020</last_update_submitted>
  <last_update_submitted_qc>September 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cognitive function</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclobenzaprine</mesh_term>
    <mesh_term>Tolperisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT03353922/Prot_ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT03353922/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Randomized 3-way cross-over of multiple doses of 150 mg tolperisone, 10 mg cyclobenzaprine, or placebo TID in 35 male &amp; female healthy volunteers. Treatment groups A (Tolperisone), B (Cyclobenzaprine), and C (Placebo) randomized by 6 treatment sequences. Subjects serve as own positive control, data analyzed and reported based on treatment type.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ABC (Tolperisone, Cyclobenzaprine, Placebo)</title>
          <description>1st intervention: 150 mg tolperisone tablets administered every 8 hours for 3 days, followed by washout period of 4 days, then 2nd intervention: 10 mg cyclobenzaprine every 8 hours for 3 days, followed by 4 day washout, then 3rd intervention: placebo every 8 hours for 3 days, followed by release from clinic.</description>
        </group>
        <group group_id="P2">
          <title>ACB (Tolperisone, Placebo, Cyclobenzaprine)</title>
          <description>1st intervention: 150 mg tolperisone tablets administered every 8 hours for 3 days, followed by washout period of 4 days, then 2nd intervention: placebo every 8 hours for 3 days, followed by 4 day washout, then 3rd intervention: 10 mg cyclobenzaprine every 8 hours for 3 days, followed by release from clinic.</description>
        </group>
        <group group_id="P3">
          <title>BAC (Cyclobenzaprine, Tolperisone, Placebo)</title>
          <description>1st intervention: 10 mg cyclobenzaprine tablets administered every 8 hours for 3 days, followed by washout period of 4 days, then 2nd intervention: 150 mg tolperisone cyclobenzaprine every 8 hours for 3 days, followed by 4 day washout, then 3rd intervention: placebo every 8 hours for 3 days, followed by release from clinic.</description>
        </group>
        <group group_id="P4">
          <title>BCA (Cyclobenzaprine, Placebo, Tolperisone)</title>
          <description>1st intervention: 10 mg cyclobenzaprine tablets administered every 8 hours for 3 days, followed by washout period of 4 days, then 2nd intervention: placebo every 8 hours for 3 days, followed by 4 day washout, then 3rd intervention: 150 mg tolperisone every 8 hours for 3 days, followed by release from clinic.</description>
        </group>
        <group group_id="P5">
          <title>CAB (Placebo, Tolperisone, Cyclobenzaprine)</title>
          <description>1st intervention: placebo tablets administered every 8 hours for 3 days, followed by washout period of 4 days, then 2nd intervention: 150 mg tolperisone every 8 hours for 3 days, followed by 4 day washout, then 3rd intervention: 10 mg cyclobenzaprine every 8 hours for 3 days, followed by release from clinic.</description>
        </group>
        <group group_id="P6">
          <title>CBA (Placebo, Cyclobenzaprine, Tolperisone)</title>
          <description>1st intervention: placebo tablets administered every 8 hours for 3 days, followed by washout period of 4 days, then 2nd intervention: 10 mg cyclobenzaprine every 8 hours for 3 days, followed by 4 day washout, then 3rd intervention: 150 mg tolperisone every 8 hours for 3 days, followed by release from clinic.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Final analysis on per protocol population (n=33) instead of ITT (n=35) due to 2 subjects being mis-dosed</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All Study Participants; n=33</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Final analysis on per protocol population (n=33) instead of ITT (n=35) due to 2 subjects being mis-dosed</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Cross over design for subjects, not independent groups</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Final analysis on per protocol population (n=33) instead of ITT (n=35) due to 2 subjects being mis-dosed</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Final analysis on per protocol population (n=33) instead of ITT (n=35) due to 2 subjects being mis-dosed</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>kg/m2</description>
          <population>Final analysis on per protocol population (n=33) instead of ITT (n=35) due to 2 subjects being mis-dosed</population>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.012" spread="2.959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Standard Deviation of Lateral Position (SDLP)</title>
        <description>In this crossover study, treatment effects were assessed following initial dose, the morning following nighttime dosing (to assess residual next day effects), and at steady state (i.e., following AM dosing on Day 3).</description>
        <time_frame>at time of peak concentration of drug (Tmax) on Day 1</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Tolperisone HCl 150 mg</title>
            <description>150 mg tolperisone tablets administered by mouth every 8 hours for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Tablet</title>
            <description>sugar pills administered by mouth every 8 hours for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cyclobenzaprine 10 mg Oral Tablet</title>
            <description>10 mg cyclobenzapine tablets administered by mouth every 8 hours for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Standard Deviation of Lateral Position (SDLP)</title>
          <description>In this crossover study, treatment effects were assessed following initial dose, the morning following nighttime dosing (to assess residual next day effects), and at steady state (i.e., following AM dosing on Day 3).</description>
          <population>per protocol</population>
          <units>cm of deviation of lateral position</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3" spread="6.25"/>
                    <measurement group_id="O2" value="29.7" spread="6.37"/>
                    <measurement group_id="O3" value="38.6" spread="12.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standard Deviation of Lateral Position (SDLP) in Simulated Driving Test of Tolperisone Compared to Placebo on Day 2 Next Day Residual Effect</title>
        <description>SDLP measured by simulated driving performance of tolperisone compared to placebo on Day 2 prior to morning dosing to determine the next day residual effect or hangover of treatment</description>
        <time_frame>in the morning predose on Day 2 following nighttime dosing</time_frame>
        <population>Per protocol population was analyzed per treatment group, therefore all subjects completing a treatment were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Tolperisone HCl 150 mg</title>
            <description>150 mg tolperisone tablets or cyclobenzaprine 10 mg oral tablet administered by mouth every 8 hours for 3 days&#xD;
Cyclobenzaprine 10 Mg Oral Tablet: cyclobenzaprine 10 mg tablets&#xD;
Placebo Oral Tablet: sugar pill</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Tablet</title>
            <description>sugar pills administered by mouth every 8 hours for 3 days&#xD;
Cyclobenzaprine 10 Mg Oral Tablet: cyclobenzaprine 10 mg tablets&#xD;
Placebo Oral Tablet: sugar pill</description>
          </group>
          <group group_id="O3">
            <title>Cyclobenzaprine 10 mg Oral Tablet</title>
            <description>10 mg cyclobenzapine tablets administered by mouth every 8 hours for 3 days&#xD;
Placebo Oral Tablet: sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Standard Deviation of Lateral Position (SDLP) in Simulated Driving Test of Tolperisone Compared to Placebo on Day 2 Next Day Residual Effect</title>
          <description>SDLP measured by simulated driving performance of tolperisone compared to placebo on Day 2 prior to morning dosing to determine the next day residual effect or hangover of treatment</description>
          <population>Per protocol population was analyzed per treatment group, therefore all subjects completing a treatment were included in the analysis</population>
          <units>cm of deviation from lateral position</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" spread="7.08"/>
                    <measurement group_id="O2" value="29.9" spread="7.71"/>
                    <measurement group_id="O3" value="35.1" spread="10.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleepiness Endpoint Karolinska Sleepiness Scale KSS</title>
        <description>assessment of self-reported motivation for driving performance where 1 equals alert and 9 equals extremely sleepy</description>
        <time_frame>at Tmax on Day 1</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Tolperisone HCl 150 mg</title>
            <description>150 mg tolperisone tablets or cyclobenzaprine 10 mg oral tablet administered by mouth every 8 hours for 3 days&#xD;
Cyclobenzaprine 10 Mg Oral Tablet: cyclobenzaprine 10 mg tablets&#xD;
Placebo Oral Tablet: sugar pill</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Tablet</title>
            <description>sugar pills administered by mouth every 8 hours for 3 days&#xD;
Cyclobenzaprine 10 Mg Oral Tablet: cyclobenzaprine 10 mg tablets&#xD;
Placebo Oral Tablet: sugar pill</description>
          </group>
          <group group_id="O3">
            <title>Cyclobenzaprine 10 mg Oral Tablet</title>
            <description>10 mg cyclobenzapine tablets administered by mouth every 8 hours for 3 days&#xD;
Placebo Oral Tablet: sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Sleepiness Endpoint Karolinska Sleepiness Scale KSS</title>
          <description>assessment of self-reported motivation for driving performance where 1 equals alert and 9 equals extremely sleepy</description>
          <population>per protocol</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="1.96"/>
                    <measurement group_id="O2" value="3.4" spread="1.99"/>
                    <measurement group_id="O3" value="5.6" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steady State Standard Deviation of Lateral Position (SDLP) Day 3</title>
        <description>SDLP measured on Day 3 at steady state following 3 days of dosing three times per day to achieve steady state drug concentration and effect on outcomes</description>
        <time_frame>Day 3</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Tolperisone HCl 150 mg</title>
            <description>150 mg tolperisone tablets or cyclobenzaprine 10 mg oral tablet administered by mouth every 8 hours for 3 days&#xD;
Cyclobenzaprine 10 Mg Oral Tablet: cyclobenzaprine 10 mg tablets&#xD;
Placebo Oral Tablet: sugar pill</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Tablet</title>
            <description>sugar pills administered by mouth every 8 hours for 3 days&#xD;
Cyclobenzaprine 10 Mg Oral Tablet: cyclobenzaprine 10 mg tablets&#xD;
Placebo Oral Tablet: sugar pill</description>
          </group>
          <group group_id="O3">
            <title>Cyclobenzaprine 10 mg Oral Tablet</title>
            <description>10 mg cyclobenzapine tablets administered by mouth every 8 hours for 3 days&#xD;
Placebo Oral Tablet: sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Steady State Standard Deviation of Lateral Position (SDLP) Day 3</title>
          <description>SDLP measured on Day 3 at steady state following 3 days of dosing three times per day to achieve steady state drug concentration and effect on outcomes</description>
          <population>ITT</population>
          <units>cm deviation from lateral position</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8" spread="6.68"/>
                    <measurement group_id="O2" value="29.6" spread="7.46"/>
                    <measurement group_id="O3" value="31.7" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The total duration of study participation was approximately 4 weeks including screening to follow up.</time_frame>
      <desc>No difference in definition.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tolperisone HCl 150 mg</title>
          <description>150 mg tolperisone tablets administered by mouth every 8 hours for 3 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo Oral Tablet</title>
          <description>sugar pills administered by mouth every 8 hours for 3 days</description>
        </group>
        <group group_id="E3">
          <title>Cyclobenzaprine 10 mg Oral Tablet</title>
          <description>10 mg cyclobenzapine tablets administered by mouth every 8 hours for 3 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>frequent bowel movement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>sluggishness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <description>dizziness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>somnolence</sub_title>
                <description>sleepiness</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>disturbance inattention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dry throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>skin exfoliation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hyperhydrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Judy Caron, Chief Operating Officer</name_or_title>
      <organization>Neurana Pharmaceuticals</organization>
      <phone>(617) 640-5043</phone>
      <email>jcaron@neuranapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

